Psychological morbidity and impaired quality of life in patients with stable treatment for primary adrenal insufficiency: Cross-sectional study and review of the literature

European Journal of Endocrinology

Volumn 171, Issue 2, 2014, Pages 171-182

  Tiemensma, Jitske ^a,b   Andela, Cornelie D ^a   Kaptein, Ad A ^a   Romijn, Johannes A ^c   Van Der Mast, Roos C ^a   Biermasz, Nienke R ^a   Pereira, Alberto M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; FLUDROCORTISONE; HYDROCORTISONE; LEVOTHYROXINE; ORAL CONTRACEPTIVE AGENT; PRASTERONE;

ADRENAL INSUFFICIENCY; ADULT; ANXIETY; APATHY; APATHY SCALE; AROUSAL; ARTICLE; AUTOMUTILATION; BEHAVIOR DISORDER; COMPULSION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DIMENSIONAL ASSESSMENT OF PERSONALITY PATHOLOGY SHORT FORM; EMOTIONAL ATTACHMENT; EMOTIONALITY; EUROQOL 5D; FATIGUE; FEMALE; HASHIMOTO DISEASE; HEALTH STATUS; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IDENTITY; IRRITABILITY; IRRITABILITY SCALE; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MOOD AND ANXIETY SYMPTOMS QUESTIONNAIRE SHORT FORM; MORBIDITY; MOTIVATION; MULTIDIMENSIONAL FATIGUE INVENTORY; NARCISSISM; NOTTINGHAM HEALTH PROFILE; PERSONALITY; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PHYSICAL SYMPTOM CHECKLIST; PREVALENCE; PRIMARY ADRENAL INSUFFICIENCY; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; QUESTIONNAIRE; ROLE PLAYING; SHORT FORM 36; SOCIAL AVOIDANCE BEHAVIOR; SOCIAL INTERACTION; SOCIAL REJECTION; SUBSTITUTION THERAPY; VISUAL ANALOG SCALE;

ADDISON DISEASE; ADULT; CROSS-SECTIONAL STUDIES; FEMALE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; MALE; MENTAL DISORDERS; MIDDLE AGED; NETHERLANDS; PERSONALITY; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84905238562     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0023     Document Type: Article

References (57)

1. De Kloet ER, Vreugdenhil E, Oitzl MS & Joels M. Brain corticosteroid receptor balance in health and disease. Endocrine Reviews 1998 19 269-301. (doi:10.1210/edrv.19.3.0331)
2. Feelders RA, Pulgar SJ, Kempel A & Pereira AM. The burden of Cushing's disease: clinical and health-related quality of life aspects. European Journal of Endocrinology 2012 167 311-326. (doi:10.1530/EJE-11-1095)
3. Tiemensma J, Biermasz NR, Middelkoop HA, van der Mast RC, Romijn JA & Pereira AM. Increased prevalence of psychopathology and maladaptive personality traits after long-term cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2010 95 E129-E141. (doi:10.1210/jc.2010-0512)
4. Van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW & Romijn JA. Quality of life in patients after long-term biochemical cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2005 90 3279-3286. (doi:10.1210/jc.2004-1375)
5. Van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H et al. Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clinical Endocrinology 2008 69 775-784. (doi:10.1111/j.1365-2265.2008.03288.x)
6. Wagenmakers MA, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M & Hermus AR. Impaired quality of life in patients in long-term remission of Cushing's syndrome of both adrenal and pituitary origin: a remaining effect of long-standing hypercortisolism? European Journal of Endocrinology 2012 167 687-695. (doi:10.1530/EJE-12-0308)
7. Ragnarsson O, Berglund P, Eder DN & Johannsson G. Long-term cognitive impairments and attentional deficits in patients with Cushing's disease and cortisol-producing adrenal adenoma in remission. Journal of Clinical Endocrinology and Metabolism 2012 97 E1640-E1648. (doi:10.1210/jc.2012-1945)
8. Heijmans M & de Ridder D. Assessing illness representations of chronic illness: explorations of their disease-specific nature. Journal of Behavioral Medicine 1998 21 485-503. (doi:10.1023/A:1018788427100)
9. Alonso N, Granada ML, Lucas A, Salinas I, Reverter J, Oriol A & Sanmarti A. Evaluation of two replacement regimens in primary adrenal insufficiency patients. effect on clinical symptoms, health-related quality of life and biochemical parameters. Journal of Endocrinological Investigation 2004 27 449-454. (doi:10.1007/BF03345290)
10. Bleicken B, Hahner S, Loeffler M, Ventz M, Allolio B & Quinkler M. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. European Journal of Endocrinology 2008 159 811-817. (doi:10.1530/EJE-08-0578)
11. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B & Quinkler M. Influence of hydrocortisone dosage scheme on health-related quality of life in patients with adrenal insufficiency. Clinical Endocrinology 2010 72 297-304. (doi:10.1111/j.1365-2265.2009.03596.x)
12. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J, Fougner KJ, Berg TJ, Bollerslev J, Mella B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. Journal of Clinical Endocrinology and Metabolism 2009 94 4882-4890. (doi:10.1210/jc.2009-1368)
13. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA, Compston JE, Herbert J & Chatterjee VK. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism 2008 93 400-409. (doi:10.1210/jc.2007- 1134)
14. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker A-C, Quinkler M, Decker O, Arlt W & Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. Journal of Clinical Endocrinology and Metabolism 2007 92 3912-3922. (doi:10.1210/jc.2007-0685)
15. Reisch N, Hahner S, Bleicken B, Flade L, Pe drosaGil F, Loeffler M, Ventz M, Hinz A, Beuschlein F, Allolio B et al. Quality of life is less impaired in adults with congenital adrenal hyperplasia because of 21-hydroxylase deficiency than in patients with primary adrenal insufficiency. Clinical Endocrinology 2011 74 166-173. (doi:10.1111/j.1365-2265.2010.03920.x)
16. Thomsen AF, Kvist TK, Andersen PK & Kessing LV. The risk of affective disorders in patients with adrenocortical insufficiency. Psychoneuroendocrinology 2006 31 614-622. (doi:10.1016/j.psyneuen.2006.01.003)
17. Arlt W, Callies F & Allolio B. DHEA replacement in women with adrenal insufficiency - pharmacokinetics, bioconversion and clinical effects on well-being, sexuality and cognition. Endocrine Research 2000 26 505-511. (doi:10.3109/07435800009048561)
18. Arlt W, Callies F, van Vlijmen JC, Koehler I, Reincke M, Bidlingmaier M, Huebler D, Oettel M, Ernst M, Schulte HM et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. New England Journal of Medicine 1999 341 1013-1020. (doi:10.1056/NEJM199909303411401)
19. Hunt PJ, Gurnell EM, Huppert FA, Richards C, Prevost AT, Wass JA, Herbert J & Chatterjee VK. Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. Journal of Clinical Endocrinology and Metabolism 2000 85 4650-4656. (doi:10.1210/jcem.85.5.6588)
20. Harbeck B, Kropp P & Mönig H. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. Applied Psychophysiology and Biofeedback 2009 34 113-119. (doi:10.1007/s10484-009-9082- 5)
21. Starkstein SE, Petracca G, Chemerinski E & Kremer J. Syndromic validity of apathy in Alzheimer's disease. American Journal of Psychiatry 2001 158 872-877. (doi:10.1176/appi.ajp.158.6.872)
22. Chatterjee A, Anderson KE, Moskowitz CB, Hauser WA & Marder KS. A comparison of self-report and caregiver assessment of depression, apathy, and irritability in Huntington's disease. Journal of Neuropsychiatry and Clinical Neurosciences 2005 17 378-383. (doi:10.1176/appi.neuropsych.17.3.378)
23. Clark LA & Watson D. Tripartite model of anxiety and depression: psychometric evidence and taxonomic implications. Journal of Abnormal Psychology 1991 100 316-336. (doi:10.1037/0021-843X.100.3.316)
24. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE & Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychological Medicine 1997 27 363-370. (doi:10.1017/S0033291796004382)
25. Zigmond AS & Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandinavica 1983 67 361-370. (doi:10.1111/j.1600-0447.1983. tb09716.x)
26. Smets EM, Garssen B, Bonke B & De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Journal of Psychosomatic Research 1995 39 315-325. (doi:10.1016/0022- 3999(94)00125-O)
27. Ware JE & Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992 30 473-483. (doi:10.1097/00005650-199206000-00002)
28. Brazier JE, Harper R, Jones NM, O'Cathain A, Thomas KJ, Usherwood T & Westlake L. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992 305 160-164. (doi:10.1136/bmj.305.6846.160)
29. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy (New York) 1990 16 199-208. (doi:10.1016/0168-8510(90)90421-9)
30. Hunt SM, McKenna SP, McEwen J, Backett EM, Williams J & Papp E. A quantitative approach to perceived health status: a validation study. Journal of Epidemiology and Community Health 1980 34 281-286. (doi:10.1136/jech.34.4.281)
31. Hunt SM & McEwen J. The development of a subjective health indicator. Sociology of Health & Illness 1980 2 231-246. (doi:10.1111/1467-9566. ep11340686)
32. American Psychiatric Association. In Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington D.C.: APA, 1980.
33. de Waal MW, Arnold IA, Spinhoven P, Eekhof JA & van Hemert AM. The reporting of specific physical symptoms for mental distress in general practice. Journal of Psychosomatic Research 2005 59 89-95. (doi:10.1016/j.jpsychores. 2005.02.011)
34. Van Kampen D, de Beurs E & Andrea H. A short form of the Dimensional Assessment of Personality Pathology-Basic Questionnaire (DAPP-BQ): the DAPP-SF. Psychiatry Research 2008 160 115-128. (doi:10.1016/j.psychres.2007.05.002)
35. Pereira AM, Tiemensma J & Romijn JA. Neuropsychiatric disorders in Cushing's syndrome. Neuroendocrinology 2010 92 65-70. (doi:10.1159/000314317)
36. Løvås K, Loge JH & Husebye ES. Subjective health status in Norwegian patients with Addison's disease. Clinical Endocrinology 2002 56 581-588. (doi:10.1046/j.1365-2265.2002.01466.x)
37. Benson S, Neumann P, Unger N, Schedlowski M, Mann K, Elsenbruch S & Petersenn N. Effects of standard glucocorticoid replacement therapies on subjective well-being: a randomized, double-blind, crossover study in patients with secondary adrenal insufficiency. European Journal of Endocrinology 2012 167 679-685. (doi:10.1530/EJE-12-0351)
38. Forss M, Batcheller G, Skrtic S & Johannsson G. Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency - a worldwide patient survey. BMC Endocrine Disorders 2012 12 8. (doi:10.1186/1472-6823-12-8)
39. Riedel M, Wiese A, Schürmeyer TH & Brabant G. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes. Experimental and Clinical Endocrinology 1993 101 106-111. (doi:10.1055/s-0029-1211215)
40. Ekman B, Bachrach-Lindström M, Lindström T, Wahlberg J, Blomgren J & Arnqvist HJ. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency. Clinical Endocrinology 2012 77 18-25. (doi:10.1111/j.1365-2265.2012.04352.x)
41. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman B, Engström BE, Olsson T, Ragnarsson O, Ryberg M et al. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. Journal of Clinical Endocrinology and Metabolism 2012 97 473-481. (doi:10.1210/jc.2011-1926)
42. Løvås K & Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. European Journal of Endocrinology 2007 157 109-112. (doi:10.1530/EJE-07-0052)
43. Oksnes M, Björnsdottir S, Isaksson M, Methlie P, Carlsen S, Nilsen RM, Broman JE, Triebner K, Kampe O, Hulting AL et al. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of Addison's disease: a randomized clinical trial. Journal of Clinical Endocrinology and Metabolism 2014 99 1665-1674. (doi:10.1210/jc.2013-4253)
44. Meyer G, Hackemann A, Penna-Martinez M & Badenhoop K. What affects the quality of life in autoimmune Addison's disease? Hormone and Metabolic Research 2013 45 92-95. (doi:10.1055/s-0032-1331766)
45. Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA & Biermasz NR. Affected illness perceptions and the association with impaired quality of life in patients with long-term remission of acromegaly. Journal of Clinical Endocrinology and Metabolism 2011 96 3550-3558. (doi:10.1210/jc.2011-1645)
46. Newman S, Steed L & Mulligan K. Self-management interventions for chronic illness. Lancet 2004 364 1523-1537. (doi:10.1016/S0140-6736(04)17277-2)
47. Taylor SJ, Sohanpal R, Bremner SA, Devine A, McDaid D, Fernández J-L, Griffiths CJ & Eldridge S. Self-management support for moderate-to-severe chronic obstructive pulmonary disease: a pilot randomised controlled trial. British Journal of General Practice 2012 62 e687-e695. (doi:10.3399/bjgp12X656829)
48. Loh SY, Packer T, Chinna K & Quek KF. Effectiveness of a patient self-management programme for breast cancer as a chronic illness: a non-randomised controlled clinical trial. Journal of Cancer Survivorship 2013 7 331-342. (doi:10.1007/s11764-013-0274-x)
49. Groves RW, Toms GC, Houghton BJ & Monson JP. Corticosteroid replacement therapy: twice or thrice daily? Journal of the Royal Society of Medicine 1988 81 514-516. (doi:10.1177/014107688808100906)
50. Heijmans M & De Ridder D. Structure and determinants of illness representations in chronic disease: a comparison of Addison's disease and chronic fatigue syndrome. Journal of Health Psychology 1998 3 523-537. (doi:10.1177/135910539800300406)
51. Heijmans M. The role of patients' illness representations in coping and functioning with Addison's disease. British Journal of Health Psychology 1999 4 137-149. (doi:10.1348/135910799168533)
52. Libè R, Barbetta L, Dall'Asta C, Salvaggio F, Gala C, Beck-Peccoz P & Ambrosi B. Effects of dehydroepiandrosterone (DHEA) supplementation on hormonal, metabolic and behavioral status in patients with hypoadrenalism. Journal of Endocrinological Investigation 2004 27 736-741. (doi:10.1007/ BF03347515)
53. Bleicken B, Hahner S, Ventz M & Quinkler M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients. American Journal of the Medical Sciences 2010 339 525-531. (doi:10.1097/MAJ. 0b013e3181db6b7a)
54. Warmuz-Stangierska I, Baszko-Błaszyk D & Sowiński J. Emotions and features of temperament in patients with Addison's disease. Endokrynologia Polska 2010 61 90-92.
55. Ekman B, Alstrand N, Bachrach-Lindström M, Jenmalm MC & Wahlberg J. Altered chemokine Th1/Th2 balance in Addison's disease: relationship with hydrocortisone dosing and quality of life. Hormone and Metabolic Research 2013 46 48-53. (doi:10.1055/s-0033-1351291)
56. Langenheim J, Ventz M, Hinz A & Quinkler M. Modified-release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Hormone and Metabolic Research 2013 45 96-101. (doi:10.1055/s-0032-1316293)
57. Smans L, Lentjes E, Hermus A & Zelissen P. Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease. Hormones 2013 12 93-100.